Work

mRNA CAR T cells promote tolerable, tunable therapy in preclinical high grade glioma models

Year: 2026

Type: article

Abstract: Cell therapies have introduced a critically needed therapeutic option for pediatric patients with high-grade glioma (HGG), providing hope to many patients and their families.1 There are no known curative therapies for HGG, a devastating central nervous system (CNS) tumor that occurs in children and young adults. Early signals suggest that treatment with chimeric antigen receptor T (CAR T) cells delivered directly to the CNS may induce tumor regression. A pioneering clinical trial evaluating lentiviral GD2-directed CAR T cells in patients with diffuse midline glioma (DMG) demonstrated favorable tumor response in multiple patients.

Source: Molecular Therapy Oncology

DOI: 10.1016/j.omton.2026.201273

Authors: Monica Pomaville, Jessica B. Foster

Institutions: Children's Hospital of Philadelphia, University of Pennsylvania

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,900